News
NCNA
1.590
-0.63%
-0.010
Weekly Report: what happened at NCNA last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at NCNA last week (0608-0612)?
Weekly Report · 06/15 10:00
NuCana Shareholders Approve All Resolutions at June 2026 AGM
TipRanks · 06/08 12:15
Weekly Report: what happened at NCNA last week (0601-0605)?
Weekly Report · 06/08 09:57
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 06/04 21:05
NuCana appoints Ian Webster as CFO
TipRanks · 06/01 12:43
NuCana Confirms Ian Webster as CFO to Steer Oncology Pipeline Through Key 2026 Milestones
TipRanks · 06/01 12:31
NuCana Appoints Ian Webster CFO, Effective Immediately
Benzinga · 06/01 12:11
NuCana names Ian Webster CFO after interim stint
PUBT · 06/01 12:00
NUCANA APPOINTS IAN WEBSTER AS CHIEF FINANCIAL OFFICER
Reuters · 06/01 12:00
Weekly Report: what happened at NCNA last week (0525-0529)?
Weekly Report · 06/01 10:00
Weekly Report: what happened at NCNA last week (0518-0522)?
Weekly Report · 05/25 10:02
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 05/18 21:05
Weekly Report: what happened at NCNA last week (0511-0515)?
Weekly Report · 05/18 10:02
UK's NuCana Q1 net loss widens; cash runway extends to 2029
Reuters · 05/14 22:06
NUCANA Q1 NET INCOME GBP -3.9 MILLION
Reuters · 05/14 21:58
NuCana Posts Wider Q1 2026 Loss as Cash Balance Declines
TipRanks · 05/14 21:34
NuCana Q1 FY26 loss widens to £3.87 million
PUBT · 05/14 20:46
NuCana GAAP EPS of £0.00
Seeking Alpha · 05/14 20:35
Weekly Report: what happened at NCNA last week (0504-0508)?
Weekly Report · 05/11 10:00
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.